secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001437749-23-018164
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals: Phase 3 RECOVER study enrollment exceeds 80%; topline data expected Q3 2023
--------------------------------------------------------------------------------

- Over 80% of patients enrolled in pivotal Phase 3 RECOVER study of brilaroxazine for schizophrenia; enrollment ongoing in US, Europe, Asia.
- Topline data from the ~400-patient placebo-controlled trial expected in Q3 2023.
- Company also reports $5.7M in gross proceeds from Q2 2023 warrant exercises: $4.74M from common warrants at $2.40/share and $0.915M from investor warrants at $4.125/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923018164/0001437749-23-018164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923018164/rvph20230621_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-018164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer